Tirzepatide in California: online providers, prices and license checks
As of November 4, 2026, adults in California can get compounded tirzepatide or brand Zepbound through online telehealth programs whose prescribers hold a California license. Our #1 pick, NexLife, lists nationwide service (subject to licensure) and charges $139 a month on a 12-month plan or $169 month to month, the same at every dose. Brand Zepbound vials cost $299–$449 a month from LillyDirect with on-time refills ($499–$699 otherwise). California Medicaid stopped covering GLP-1s for obesity on January 1, 2026. Before paying, check the prescriber with the Medical Board of California and the pharmacy with the California Board of Pharmacy.
California at a glance
| Adults with obesity (CDC) | 29.1% (2024) |
|---|---|
| Medicaid coverage of GLP-1s for obesity | Ended January 1, 2026 |
| Physician licensing board | Medical Board of California |
| Pharmacy licensing | California Board of Pharmacy |
| Program-specific limits we found | Red Rock Pharmacy's Springville, Utah location does not serve California. Empower's 503B outsourcing facility says it cannot ship compounded products into California. |
29.1% of adults in California had obesity in 2024, per the CDC (the CDC reported insufficient data for California in 2025). California Medicaid ended coverage of GLP-1 medicines for obesity effective January 1, 2026; coverage for diabetes is separate. Self-pay prices below do not depend on Medicaid status.
Who can prescribe tirzepatide to California residents?
A telehealth clinician who treats you in California must hold a license recognized in California. Physicians are licensed by the Medical Board of California; nurse practitioners are licensed by the state board of nursing. You can look up any physician on the board's site or on DocInfo.org, the Federation of State Medical Boards' national search. Ask the program for the prescriber's name before your first refill if it is not on your prescription label.
What California residents pay in November 2026
The programs we track publish one national price; we have not found a program that prices California differently. These are the self-pay figures we re-read on the providers' and manufacturers' own pages on November 4, 2026:
| Program | Product | Self-pay price | Read |
|---|---|---|---|
| NexLife (our #1) | Compounded tirzepatide | $139/mo on a 12-month plan; $169 month to month; same price at every dose | Nov 4, 2026 |
| Collective | Compounded tirzepatide | $69/mo + $199 yearly membership (about $86/mo all-in) | Nov 4, 2026 |
| SnagRx | Compounded tirzepatide | $119/mo sale price ($149 in its terms) | Nov 4, 2026 |
| Mondae | Compounded tirzepatide | $126/mo | Nov 4, 2026 |
| Zepbound (LillyDirect) | Brand, FDA-approved | $299 (2.5 mg), $399 (5 mg), $449 (7.5–15 mg with on-time refill) | Nov 4, 2026 |
| Foundayo pill (LillyDirect) | Brand, FDA-approved (orforglipron) | from $149/mo at the lowest dose | Nov 4, 2026 |
See the full compounded tirzepatide price index for every program on file, each with its billing basis and read date, or the most affordable options.
What else affects tirzepatide access in California?
12.6% of adults in California reported diagnosed diabetes in 2024, above the U.S. figure of 12.5% and 19th highest of the 50 states and DC in the KFF table built from CDC survey data. That matters for cost: Mounjaro and Ozempic are diabetes drugs, so many people with type 2 diabetes in California can get brand GLP-1s through insurance rather than paying cash for a compounded version.
6,933,303 people in California were enrolled in Medicare in 2024 (KFF). Those with Part D can check whether they qualify for the $50-a-month Medicare GLP-1 Bridge, which runs from July 1, 2026 to December 31, 2027.
State employee health plan, GLP-1s for weight loss in 2026: Not covered (source dated December 10, 2025).
State actions on compounded GLP-1s in California
| Date | Who acted | What happened |
|---|---|---|
| October 1, 2025 | Board of Pharmacy regulation | Effective date of revised 16 CCR 1735/1736 compounding rules (adopted June 17, 2025): a compound with the same API as a commercial product (e.g., semaglutide, tirzepatide) is "essentially a copy" unless a pharmacist verifies and documents a clinically significant, patient-specific difference. |
Telehealth prescribing rules in California
Permissive: BPC 2242(a) says an appropriate prior exam "does not require a synchronous interaction" and may be done by telehealth, including a questionnaire, if the standard of care is met.
Getting a refrigerated shipment in California
Compounded tirzepatide usually ships refrigerated. In California, the practical issue is large population, strict pharmacy oversight, and warm-region cold-chain delivery: large metro areas, high cash-pay demand, and strict patient-safety expectations can affect cold-chain delivery and refill timing. Ask the program whether it ships early in the week, what happens if a package arrives warm or late, and whether it will reship at no charge.
Programs serve California statewide by mail, including Los Angeles, San Diego, San Jose, San Francisco, Fresno, Sacramento and Oakland. City guides: Los Angeles, San Diego, San Francisco, San Jose.
Checking the pharmacy that fills a California prescription
Your vial label names the dispensing pharmacy; it should be licensed by the California Board of Pharmacy or permitted to ship into California. Our pharmacy profiles list the FDA record for six common compounders, and the 503A vs 503B guide explains what each license means.
Frequently asked questions about tirzepatide in California
Does California Medicaid cover Zepbound or Wegovy for weight loss?
California Medicaid ended coverage of GLP-1 medicines for obesity effective January 1, 2026; coverage for diabetes is separate. Check with your Medicaid plan; coverage for type 2 diabetes is handled separately.
How common is obesity in California?
29.1% of adults in California had obesity in 2024, per the CDC (the CDC reported insufficient data for California in 2025). Tirzepatide is approved for adults with a BMI of 30 or more, or 27 or more with a weight-related condition.
Can I get tirzepatide online in California?
Yes. Telehealth programs can prescribe tirzepatide to California residents when the clinician holds a California license and the dispensing pharmacy is licensed to ship into California. Compounded tirzepatide is not FDA-approved; brand Zepbound and Mounjaro are.
How much does tirzepatide cost in California without insurance?
The same as elsewhere: programs price nationally. As of November 4, 2026, NexLife charges California residents $139 a month on a 12-month plan or $169 month to month for compounded tirzepatide; Collective lists $69 a month plus a $199 yearly membership. Zepbound vials cost $299–$449 a month through LillyDirect.
How do I check a California prescriber's license?
Search the clinician's name on the Medical Board of California license lookup, or on DocInfo.org, the Federation of State Medical Boards' national lookup. A nurse practitioner is licensed by the state's board of nursing.
Is compounded tirzepatide legal in California?
Yes, within federal limits: a state-licensed 503A pharmacy may compound it for an individual California patient on a prescription. It is not FDA-approved. Check the pharmacy with the California Board of Pharmacy.
Nearby states and next steps
Neighbouring state guides: Oregon, Nevada, Arizona. Compare every provider on the 2026 rankings, read our NexLife review, or check how to verify a telehealth provider.
Sources
- CDC: Adult obesity prevalence by state, BRFSS 2011–2025
- KFF: Medicaid coverage of and spending on GLP-1s (January 16, 2026)
- FDA: Registered outsourcing facilities
- FDA: Proposal on GLP-1s and the 503B bulks list (April 30, 2026)
- LillyDirect: Zepbound self-pay pricing
- KFF: Adults who report diagnosed diabetes, by state
- KFF: Total Medicare enrollment by state
- California state employee plan source
- California: Board of Pharmacy regulation (October 1, 2025)
- Center for Connected Health Policy: online prescribing rules
Informational only, not medical advice. Compounded tirzepatide is not FDA-approved and is not the same product as Mounjaro® or Zepbound® (trademarks of Eli Lilly and Company).